Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 3Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 28Gynecologic 6Gastrointestinal 6Other solid neoplasm 5Tumor-Agnostic 3CNS 3Thoracic 2Sarcoma 2Plasma cell 2Lymphoid 2Genitourinary 2Other hematologic neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Melanoma 1

Interventions

pembrolizumab 65Nivolumab 58Ipilimumab 32Cyclophosphamide 22Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13cemiplimab 13fludarabine 12Opdualag 12binimetinib 10Blood Specimen Collection 10aldesleukin 9Radiosurgery 9encorafenib 8Interleukin-2 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Radiotherapy 5Disulfides 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × palbociclib × Dermatologic × Clear all
NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
45 enrolled
DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡